BioNTech Net Income vs. Number Of Shares Shorted
| BNTX Stock | USD 89.20 -0.11 -0.12% |
Net Loss | First Reported 2018-03-31 | Previous Quarter -28.7 M | Current Value -302.1 M | Quarterly Volatility 1.2 B |
Macro event markers
This profitability view for BioNTech SE summarizes relationships between earnings and core financial drivers. All figures are sourced from financial reporting disclosures.
BioNTech | Build portfolio with BioNTech Stock |
Macro event markers
Quarterly Earnings Growth -0.43 | Earnings Share -5.40 | Revenue Per Share | Quarterly Revenue Growth -0.24 | Return On Assets |
BioNTech's market capitalization and book value each provide useful but distinct information about the business. BioNTech's market capitalization is 22.62 B. BioNTech P/B of 1.02 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 5.76 B. The relationship between BioNTech's intrinsic value, market price, and book value adds depth to the analysis.
Value and price for BioNTech are related but not identical, and they can diverge across cycles. For BioNTech, key inputs include a P/E ratio of 5.19, a P/B ratio of 1.02, a profit margin of -39.59%, and ROE of -5.88%. The actual BioNTech transaction price is determined by real-time order flow on the exchange.
BioNTech SE Number Of Shares Shorted vs. Net Income Fundamental Analysis
Financial ratio benchmarking estimates BioNTech's competitive valuation profile. BioNTech SE is rated below average in net income among leading competitors. It is rated below average in number of shares shorted among leading competitors . Currently, Net Loss is projected to increase significantly based on multi-year reporting trends. Year-ago financials show BioNTech with Net Loss of -1.09 Billion. Comparative earnings metrics contextualize BioNTech.BioNTech Number Of Shares Shorted vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
BioNTech |
| = | -1.09 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
BioNTech |
| = | 4.46 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
BioNTech Number Of Shares Shorted Comparison
BioNTech is currently under evaluation in number of shares shorted among leading competitors.
BioNTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioNTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioNTech will eventually generate negative long term returns. The profitability progress is the general direction of BioNTech's change in net profit over the period of time. It can combine multiple indicators of BioNTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | -1.5 B | -1.4 B | |
| Net Interest Income | -11.1 M | -10.5 M | |
| Interest Income | 503.2 M | 528.4 M | |
| Operating Income | -623.9 M | -592.7 M | |
| Net Loss | -1.1 B | -1.1 B | |
| Income Before Tax | -1 B | -958.9 M | |
| Total Other Income Expense Net | -385.5 M | -366.2 M | |
| Net Income Applicable To Common Shares | 11.8 B | 12.4 B | |
| Net Loss | -1.1 B | -1 B | |
| Income Tax Expense | 81.9 M | 77.8 M | |
| Change To Netincome | 1.4 B | 1.5 B | |
| Net Loss | -4.52 | -4.29 | |
| Income Quality | -0.40 | -0.38 | |
| Net Income Per E B T | 1.08 | 0.64 |
BioNTech Profitability Driver Comparison
Profitability drivers for BioNTech are the financial and operational factors with the greatest impact on its earnings. Investors must anticipate a wide variety of external disruptions that can affect BioNTech's profit margins, market performance, and overall investment attractiveness.
Earnings Estimation Breakdown
The projected forward EPS for BioNTech SE is -1.759 per current analyst consensus, derived from trailing twelve-month earnings data. Estimates range from -2.8137 to 0.37 across individual analysts modeling BioNTech's near-term performance. This consensus excludes one-time items to maintain a clean view of BioNTech's recurring earnings power.Last Reported EPS
-2.8137 Lowest | Expected EPS | 0.37 Highest |
Earnings Projection Consensus
When BioNTech's estimated intrinsic value exceeds its current market price, some analysts view this as a potential margin of safety. A market price above the estimated value may signal that expectations are already priced in or that overvaluation risk is present. Treat these signals as inputs to a broader investment framework, not standalone buy or sell triggers.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 19 | 42.13% | 0.0 | -1.759 | -5.4 |
Earnings History
Analyst EPS consensus for BioNTech is refreshed throughout each reporting cycle as new information reaches the market. Its primary investment use is as a benchmark: actual results above consensus signal positive execution; below signals a miss. Pairing consensus EPS with intrinsic value estimates adds a longer-term perspective to near-term earnings analysis.BioNTech Quarterly Gross Profit | 568.72 Million |
The degree to which BioNTech's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Earnings per Share Projection vs Actual
Actual EPS disclosed by BioNTech in its earnings release reflects true business profitability for the completed quarter. Analyst estimates for BioNTech SE project this figure in advance based on management commentary and financial model assumptions. Weighted share count calculation ensures that buybacks and share issuances during the period are properly captured.Estimated Months Earnings per Share
EPS is especially relevant for income investors in BioNTech because it links corporate profitability to dividend potential. A company that grows EPS consistently is better positioned to reward shareholders with increasing distributions. That said, EPS alone is insufficient - compare it with free cash flow, debt levels, and peer metrics before making income-focused decisions.Quarterly Analyst Estimates and Surprise Metrics
Quarterly EPS surprises are one of the most reliable catalysts for abrupt price moves in BioNTech. When reported results exceed analyst consensus, markets often respond with swift buying; misses typically trigger the reverse. Analyst models incorporate guidance trends, sector data, and macro assumptions to form these forward estimates.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-03-10 | 2025-12-31 | -0.2472 | -0.33 | -0.0828 | 33 | ||
2025-11-03 | 2025-09-30 | 0.1 | -0.12 | -0.22 | 220 | ||
2025-08-04 | 2025-06-30 | -1.41 | -1.6 | -0.19 | 13 | ||
2025-05-16 | 2025-03-31 | -2.3471 | -1.8208 | 0.5263 | 22 | ||
2025-03-10 | 2024-12-31 | 0.4767 | 1.08 | 0.6033 | 126 | ||
2024-11-04 | 2024-09-30 | -1.7 | 0.88 | 2.58 | 151 | ||
2024-08-05 | 2024-06-30 | -2.02 | -3.36 | -1.34 | 66 | ||
2024-05-06 | 2024-03-31 | -1.17 | -1.41 | -0.24 | 20 | ||
2024-03-20 | 2023-12-31 | 2.42 | 1.9 | -0.52 | 21 | ||
2023-11-06 | 2023-09-30 | -0.1 | 0.67 | 0.77 | 770 | ||
2023-08-07 | 2023-06-30 | -0.96 | -0.79 | 0.17 | 17 | ||
2023-05-08 | 2023-03-31 | 0.14 | 2.05 | 1.91 | 1364 | ||
2023-03-27 | 2022-12-31 | 7.99 | 9.26 | 1.27 | 15 | ||
2022-11-07 | 2022-09-30 | 4.51 | 6.98 | 2.47 | 54 | ||
2022-08-08 | 2022-06-30 | 7.08 | 6.45 | -0.63 | 8 | ||
2022-05-09 | 2022-03-31 | 9.24 | 14.24 | 5.0 | 54 | ||
2022-03-30 | 2021-12-31 | 7.44 | 12.18 | 4.74 | 63 | ||
2021-11-09 | 2021-09-30 | 11.01 | 12.35 | 1.34 | 12 | ||
2021-08-09 | 2021-06-30 | 7.58 | 10.77 | 3.19 | 42 | ||
2021-05-10 | 2021-03-31 | 3.09 | 4.39 | 1.3 | 42 | ||
2021-03-30 | 2020-12-31 | -0.15 | 1.57 | 1.72 | 1146 | ||
2020-11-10 | 2020-09-30 | -0.37 | -0.88 | -0.51 | 137 | ||
2020-08-11 | 2020-06-30 | -0.06 | -0.38 | -0.32 | 533 | ||
2020-05-12 | 2020-03-31 | -0.24 | -0.24 | 0.0 | 0 | ||
2020-03-31 | 2019-12-31 | -0.17 | -0.26 | -0.09 | 52 | ||
2019-11-14 | 2019-09-30 | -0.16 | -0.13 | 0.03 | 18 |
Use BioNTech in pair-trading
Pair analysis around BioNTech SE matters because it can turn one security idea into a more market-neutral structure. The advantage is that adverse movement in one leg may be partly offset by the other when correlation and thesis alignment hold.
BioNTech Pair Trading
BioNTech SE Pair Trading Analysis
The information in the correlation table below can inform BioNTech tax-loss harvesting decisions, showing which instruments historically move in lockstep with BioNTech SE and can serve as viable temporary replacements.
Negative correlation assets provide natural hedges against BioNTech positions. When BioNTech SE's value declines, a negatively correlated instrument tends to rise, partially offsetting portfolio losses.
BioNTech's hedging context can be framed through Correlation analysis and pair-based evaluation. Sector-level and cross-sector pair comparisons both contribute to hedging context. Hedging context is most informative when correlation patterns for BioNTech are stable.Use Investing Themes to Complement your BioNTech position
At 22.62 Billion in the Biotechnology space, BioNTech SE mid-cap profile gives investors a structured starting point for building sector-aligned themes. Building a Healthcare theme from BioNTech SE 22.62 Billion position turns a single Biotechnology conviction into a risk-managed basket.
Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 38 constituents at this time.
Investors can hold the Advertising Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.
| View All Next | Launch |